Upstream Bio, Inc.
NASDAQ:UPBBiotechnology
+$0.10 today
- Market cap
- $114.01M
- Beta
- 1.11
- P/E (TTM)
- -2.2
- EPS (TTM)
- -$2.89
Volume 1.24M
Average 0.66M
UPB Account Payables
Amounts the company owes suppliers for goods and services received.
Upstream Bio, Inc.NASDAQ: UPB
Account Payables · Q1 FY2026 · quarter ended Mar 2026
Account payables falls 63.8% from a year ago
Account payables stood at $1.71M at the end of Q1 FY2026, down 63.8% from a year earlier and down 37.3% from the prior quarter. Over 3 fiscal years it compounded at +56.4% a year.
Context
- Account payables amounted to 0.5% of total assets at the end of Q1 FY2026, down 0.5 pp from a year earlier.
- Account payables increased in 2 of the last 3 fiscal years.
What to watch
Whether account payables keeps falling in the next quarterly balance sheet after a -63.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Account Payables history
USD · from the balance sheet
- Latest · FY2025
- 2.73M USD
- Year-over-year change
- -32.5%
- 3-year CAGR
- +56.4%
| Period | Period end | Account Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.73M | -32.5% |
| FY2024 | 2024-12-31 | 4.04M | +103.1% |
| FY2023 | 2023-12-31 | 1.99M | +179.5% |
| FY2022 | 2022-12-31 | 712K | — |
Account Payables vs competitors
How UPB compares with its peers on the latest reported figures
- Peers report in different currencies, so account payables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -63.8% is the lowest of 10, against a peer median of +26.9%.
- Account payables amounts to 0.5% of total assets for UPB, versus a peer median of 1.5%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $19.06M USD | +32.8% | -2.5% | 3.3% | |
| Mar 2026 | $18.8M USD | +52.1% | +57.8% | 2.5% | |
| Mar 2026 | $16.1M USD | -52.9% | -51.6% | 1.5% | |
| Jun 2026 | $11.46M USD | +121.4% | -10.0% | 1.2% | |
| Mar 2026 | $10.84M USD | +7.9% | +56.2% | 2.3% | |
| Sep 2026 | $9.47M USD | +26.9% | +136.0% | 0.9% | |
| Mar 2026 | $8.94M USD | -55.3% | +6.9% | 1.2% | |
| Sep 2026 | €5.3M EUR | +108.2% | -5.1% | 1.8% | |
| Sep 2026 | $4.8M USD | -10.0% | -17.5% | 0.6% | |
UPBUpstream Bio, Inc. | Mar 2026 | $1.71M USD | -63.8% | +56.4% | 0.5% |
| Peer median (excluding UPB) | — | +26.9% | -2.5% | 1.5% | |
Competitors are the stored peer set for UPB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Upstream Bio, Inc.
NASDAQ:UPB
Intrinsic Alpha fair value
Locked
Current Price
$2.08
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.